The healthcare sector in India, explained

What counts as a healthcare startup in India?

A healthcare startup is a young company that tries to deliver care, medicines, diagnosis, medical products or health software in a new way. The sector is wide. It runs from a doctor-booking app to a company that makes a heart monitor, and from an online pharmacy to a lab that reads cancer genes.

StopDown groups these companies into five areas: telemedicine and primary care, diagnostics and AI-assisted care, pharma distribution and delivery, mental health and wellness, and biotech and medical devices. Each area has different customers, different rules and different ways of earning money, so each has its own guide.

Life sciences is the research side of the same sector: drug discovery, biotech, genomics and medical technology. These companies often spend years in labs and trials before they sell anything, which makes them very different from an app that books a blood test.

How did healthcare grow in India?

India has long had two health systems side by side. Government hospitals and primary health centres offer free or cheap care, but they are crowded and uneven. Private clinics and hospitals fill the gap, mostly in cities, and patients usually pay for them directly.

Startups began to matter in the 2010s. Phones got cheaper, mobile data became affordable, and UPI made small digital payments easy. Booking a doctor, ordering medicines or buying a lab test from home became normal for many urban families. Practo, which began as a doctor-search and booking platform, is a well-known example from this period.

The COVID-19 years from 2020 sped everything up. Lockdowns pushed people to video consultations, home sample collection and medicine delivery. In March 2020 the government issued Telemedicine Practice Guidelines, which for the first time said clearly that a registered doctor could treat a patient by video, phone or chat. Many companies that exist today either started or grew fast in that window.

After the rush, the sector became more careful. Investors started to ask whether a company could earn a profit on each patient or order, and not only whether it could grow. Hospital chains, diagnostic labs and home-care providers, which own real assets and real staff, received more attention. Companies in StopDown's data such as Superhealth, a hospital chain using AI in its operations, and Health Care at Home, which provides out-of-hospital rehabilitation and recovery, reflect that shift toward actual delivery of care.

Who are the customers, and who pays?

The most important fact about Indian healthcare is that most of the money comes from households. Patients pay for consultations, tests and medicines out of pocket. This is called out-of-pocket spending. Government schemes and insurance pay a smaller share, though that share is rising.

Customers fall into a few groups. Individuals and families pay directly for things such as a blood test or a therapy session. Employers pay for health checks and wellness programmes for staff. Insurers and government schemes pay for hospital treatment. Hospitals, clinics and laboratories are customers too, when a startup sells them software, equipment or supplies.

This split matters for any startup. A company that sells to a patient has to win trust one person at a time, and the patient may only need it a few times a year. A company that sells to a hospital has a longer sales process, but the contract can last for years. Innovaccer, a healthcare data analytics platform, sells mainly to healthcare organisations, so its customer is the provider, not the patient.

Government schemes shape demand. Ayushman Bharat PM-JAY gives eligible families cover for hospital treatment, and the Ayushman Bharat Digital Mission is building a common digital layer for health records. As of October 2026, the scheme's cover and eligibility are set by the government and change from time to time, so check the official site for the current terms.

How do healthcare startups make money?

There are six common ways. The first is a fee per service: a doctor's consultation, a lab test, a therapy session. The second is a margin on goods: an online pharmacy buys medicines and sells them at a price that leaves a small gap. The third is a software subscription paid by clinics, hospitals or insurers. The fourth is selling a device, plus consumables or service contracts that come with it. The fifth is a commission or listing fee from doctors or hospitals on a marketplace. The sixth is a membership or plan, where a customer pays a fixed amount for a set of services.

Margins differ sharply. Medicines are a thin-margin business because prices are controlled and discounts are common, so online pharmacies need very large volumes. Diagnostics can earn better margins when a lab runs many tests on the same machines. Software can earn the best margins but needs long sales cycles. Devices and biotech need large upfront spending on research, approvals and manufacturing.

Many companies mix these models. PharmEasy sells medicines online and its parent company, API Holdings, has also owned businesses across diagnostics and distribution. Healthians and Redcliffe Labs earn from tests, with home sample collection as a way to reach customers. Kapiva sells Ayurvedic nutrition and wellness products and so earns from consumer goods rather than clinical services.

What does the value chain look like?

Following a rupee through the sector helps. A patient first looks for information or a doctor. Then comes a consultation, followed by a test, followed by a treatment or a prescription, then a medicine or a procedure, and finally follow-up care. Each step has companies that specialise in it, and startups try to join the steps together or do one step much better.

Behind these visible steps sit the makers and suppliers: drug manufacturers, device makers and distributors who move goods to chemists and hospitals. India is a large producer of generic medicines, which are copies of drugs whose patents have ended, and the country exports them widely. That manufacturing base is one reason Indian biotech and device startups can build products at a cost that is low by global standards.

Data runs underneath all of this. Records, test results and insurance claims create the information that analytics and AI tools depend on. Innovaccer works on this layer, and 4baseCare, which does genomics-driven cancer diagnostics, turns lab data into information a doctor can act on.

Which rules and regulators matter?

Healthcare is one of the most regulated sectors. The Central Drugs Standard Control Organisation, known as CDSCO, regulates drugs and medical devices at the national level, working under the Drugs and Cosmetics Act, 1940. State drug controllers license chemists and many manufacturing sites. Prices of essential medicines are watched by the National Pharmaceutical Pricing Authority.

Doctors are regulated by the National Medical Commission and state medical councils. The 2020 Telemedicine Practice Guidelines say that only a registered medical practitioner may consult by tele-means, that the patient should consent, and that some classes of drugs may not be prescribed over a first remote consultation. Medical devices are covered by the Medical Devices Rules, 2017, which sort devices into four risk classes, from low to high, and require a licence for each.

Online medicine sales sit in a grey area. As of October 2026, there is still no separate e-pharmacy law in force. A draft e-pharmacy rule was published in 2018 and has not been finalised, so online sellers work under the general drug law and the licences of the pharmacies behind them. Courts have, at times, asked the government to act. Founders should keep a close watch here.

Health data is sensitive. The Digital Personal Data Protection Act, 2023 and its Rules, notified in November 2025, are being phased in over about 18 months, so duties on consent, security and breach reporting reach every health app in stages. The Ayushman Bharat Digital Mission lets patients create an ABHA number, a health account ID, and share records with consent. Health insurance is overseen by IRDAI, the insurance regulator. This is general information, not legal advice.

What is changing now?

Four shifts stand out. First, AI is moving into diagnosis, scheduling and hospital operations, as seen in the AI-led approach of Superhealth. Second, home-based care is growing, from sample collection to rehabilitation, because many patients and insurers prefer lower-cost settings than a hospital bed.

Third, investors are paying attention to early-stage specialised companies. Recent headlines in StopDown's data include Sunfox's Series A for its Spandan ECG device, a Series A in SuperMush led by NDude Labs, and a pre-seed round for medical-travel platform CureMeAbroad. Active investors in the last 12 months include All In Capital, 3one4 Capital, Bessemer Venture Partners, Elevation Capital, Blume Ventures, Good Capital, Zeropearl VC and Better Capital, along with angels such as Ashish Kacholia and Lashit Sanghvi. W Health Ventures describes itself as a healthcare company creation fund, a model where the fund helps start companies.

Fourth, tools for small providers are appearing. ClinikPe, which launched a platform for small diagnostic labs, is one example, and it shows how software is reaching the long tail of independent labs and clinics that large chains do not serve.

Together these shifts suggest a sector that is slowly moving from apps that sit on top of the system to companies that run parts of it.

How is a healthcare startup different from other startups?

A food-delivery or shopping app can launch in weeks and fix mistakes later. A healthcare company cannot always do that, because a mistake can hurt a person. Licences, trained staff and clinical checks come first, and that slows the early days.

The upside is that healthcare demand does not disappear in a bad year. People still fall ill, buy medicines and need tests. A company that gets the basics right can build a loyal base, because patients tend to stay with a doctor, lab or pharmacy they trust.

Hiring is also harder. A startup needs doctors, nurses, pharmacists and lab staff, who are in short supply and who must be registered with the proper councils. Many companies find that staff cost, not technology, is their largest expense.

How can you tell a strong healthcare company from a weak one?

Look first at who the customer is and how often they come back. A company that serves the same patient for years, such as a chronic-care programme, usually has steadier income than one that sells a single test.

Then look at what the company controls. Owning labs, clinics or a licensed pharmacy gives control over quality, but it costs more. Running only an app is cheaper but depends on partners. Neither is automatically better; the question is whether the company's earnings cover its costs.

Finally, look at proof. In clinical products, proof means studies, approvals and doctors who use the product daily. In consumer products, proof means repeat buyers. Claims that a product can cure a disease deserve extra caution.

Healthcare rewards patience. Trust, licences, clinical evidence and good unit economics take longer to build than in most consumer sectors. A company can look busy and still lose money on every patient, so the numbers on each consultation, test or order matter.

For readers following the news, three questions help. Who actually pays for this product? Which regulator has to say yes before it can be sold? And is the company earning money from care itself or only from attention? The answers usually explain why one company grows and another stalls.

The breakdown

Value chain: who does what, who earns

Business models

The numbers that matter

• Out-of-pocket share of spending: most health spending in India is paid directly by households, so price and trust decide demand more than insurance does.
• Gross margin per order or per test: medicines earn thin margins, diagnostics medium, software high. Check this before judging growth.
• Repeat rate: how often a patient returns, since winning a new patient is costly and care is often needed again.
• Utilisation: how busy beds, machines and doctors are, since fixed costs are high in hospitals and labs.
• Time to approval: devices, drugs and diagnostics may need months or years of approvals before the first rupee of sales.
• Collection time from insurers and hospitals: slow payment ties up cash in B2B health businesses.

Rules and regulators

Risks

• Regulation can change quickly, especially for online medicine sales and tele-consultation.
• Wrong or delayed diagnosis can harm a patient and bring legal and reputation damage.
• Thin margins and heavy discounting can make growth costly.
• Health data leaks are very damaging and carry penalties under data protection law.
• Long approval and sales cycles for devices and software can drain cash.
• Dependence on doctors, labs or hospitals that can leave or raise prices.

What to watch

• Whether a final e-pharmacy rule is notified.
• How the data protection rules are applied to health apps as the phase-in continues.
• Growth of ABHA numbers and record sharing through ABDM.
• AI tools that move from pilots to routine clinical use.
• More funding for early-stage device, diagnostic and biotech startups.
• Home care and small-lab software spreading beyond the big cities.

Inside the sector

• Telemedicine & primary care: Telemedicine and primary care startups help people see a doctor for everyday problems, by video, phone, chat or at a small clinic. They earn mainly through fees, plans and partnerships.
• Diagnostics & AI-assisted care: Diagnostics startups find out what is wrong by testing blood, images and genes, and AI-assisted care uses software to help read the results. They earn mostly per test, with software and devices on the side.
• Pharma distribution & delivery: Pharma distribution and delivery startups move medicines from manufacturers to patients, often through apps. They earn a thin margin on every pack, so they need very large volumes.
• Mental health & wellness: Mental health and wellness startups offer therapy, counselling, nutrition and lifestyle products. Some are clinical and some are consumer brands, and the rules differ for each.
• Biotech & medical devices: Biotech and medical device startups invent and make new treatments, tests and equipment. They spend years on research and approvals first, and earn later from sales, licences or partnerships.

Healthcare & Life Sciences: latest on StopDown

• B-Arm raises ₹4.8 Cr pre-Series A 10 October 2026
• Genetidoc launches online forum for rare diseases 9 October 2026
• ClinikPe launches platform for small diagnostic labs 8 October 2026
• Aiqa enters consumer health, names new CEO 7 October 2026
• Sunfox raises $7M Series A for Spandan ECG 7 October 2026
• CureMeAbroad raises $1.1M pre-seed 6 October 2026
• Kinetic Age raises $250K from AJVC, Agrasar 6 October 2026
• NDude Labs leads $3M Series A in SuperMush 6 October 2026

Every Healthcare & Life Sciences story →

Most active investors here

1. All In Capital (6 rounds)
2. 3one4 Capital (4 rounds)
3. Ashish Kacholia (4 rounds)
4. Bessemer Venture Partners (4 rounds)
5. Accel (3 rounds)
6. Better Capital (3 rounds)
7. Blume Ventures (3 rounds)
8. Elevation Capital (3 rounds)

Rounds StopDown covered in the last 12 months. Activity is not a measure of quality.